Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
January 8, 2016 8:00 am ET
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, chairman and chief executive
officer, is scheduled to present at the 34th Annual J.P.
Morgan Healthcare Conference in San Francisco on Jan. 11, 2016 at 3:00
p.m. PST (6:00 p.m. EST). During his presentation, Frazier will provide
an update on the state of the company, including accomplishments in 2015
and plans for 2016.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html.
Today’s Merck is a global health care leader working to help the world
be well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies and
animal health products, we work with customers and operate in more than
140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to health care through
far-reaching policies, programs and partnerships. For more information,
visit www.merck.com and
connect with us on Twitter, Facebook, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2014 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Lainie Keller, (908) 236-5036
Steven Cragle, (908) 740-1801
Teri Loxam, (908) 740-1986
Justin Holko, (908) 740-1879